Cargando…
Serum antibody response to BNT162b2 after natural SARS‐CoV‐2 infection
BACKGROUND: There is preliminary evidence that individuals with previous SARS‐CoV‐2 infections exhibit a more pronounced antibody response. However, these assumptions have not yet been supported by data obtained through various CE‐marked tests. This study aimed to close this gap. METHODS: Sixty‐nine...
Autores principales: | Perkmann, Thomas, Perkmann‐Nagele, Nicole, Koller, Thomas, Mucher, Patrick, Radakovics, Astrid, Wolzt, Michael, Wagner, Oswald F., Binder, Christoph J., Haslacher, Helmuth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420280/ https://www.ncbi.nlm.nih.gov/pubmed/34337738 http://dx.doi.org/10.1111/eci.13632 |
Ejemplares similares
-
Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
por: Perkmann, Thomas, et al.
Publicado: (2021) -
Comparison of five Anti-SARS-CoV-2 antibody assays across three doses of BNT162b2 reveals insufficient standardization of SARS-CoV-2 serology
por: Perkmann, Thomas, et al.
Publicado: (2023) -
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
por: Perkmann, Thomas, et al.
Publicado: (2021) -
Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
por: Perkmann, Thomas, et al.
Publicado: (2023) -
Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results
por: Perkmann, Thomas, et al.
Publicado: (2021)